ArticleViruses2023
A Cell-Adapted Live-Attenuated Vaccine Candidate Protects Pigs against the Homologous Strain VNUA-ASFV-05L1, a Representative Strain of the Contemporary Pandemic African Swine Fever Virus.
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence.Emerging microbes & infections · 2026Article
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
- Article
- ASF outbreaks in Vietnam (2019-2024): insights and lessons learned.Veterinary research communications · 2025Review
- Review
- Epidemiology and Control of African Swine Fever in Vietnam: A Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- Deletion of B125R increases protection induced by a genotype II African swine fever vaccine candidate.NPJ vaccines · 2025Article
- Development and characterization of high-efficiency cell-adapted live attenuated vaccine candidate against African swine fever.Emerging microbes & infections · 2024Article
- Article
- Development and evaluation of two rapid lateral flow assays for on-site detection of African swine fever virus.Frontiers in microbiology · 2024Article
- Article
- 2023 International African Swine Fever Workshop: Critical Issues That Need to Be Addressed for ASF Control.Viruses · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
African swine fever (ASF) is a lethal and highly contagious transboundary animal disease with the potential for rapid international spread. Currently, there is no ASF vaccine commercially available. All infected animals must be isolated and culled immediately upon the confirmation of the presence of the virus. Studies leading to the rational development of protective ASF vaccines are urgently needed. Here, we generated a safe and efficacious live-attenuated vaccine (LAV) VNUA-ASFV-LAVL2 by serially passaging a field isolate (VNUA-ASFV-05L1, genotype II) in porcine alveolar macrophages (PAMs, 65 passages) and an immortalized porcine alveolar macrophage cell line (3D4/21, 55 passages). VNUA-ASFV-LAVL2 can efficiently replicate in both PAMs and 3D4/21 cells. It provides 100% protection, even with the low dose of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.